Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Open access · greenAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 2 pooled it
15.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 2 syntheses or guidelines pooled it, 161 citations in OpenAlex.
- Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review.Cancer medicine · 2025Pooled it
- Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature.Annals of hematology · 2022Pooled it
- Trial
- Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma.Blood · 2025Trial
- Trial
- Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.The Lancet. Haematology · 2020Trial
- Trial
- Nucleoporins in Cancer: Functional Roles and Therapeutic Opportunities.Cancer discovery · 2026Article
- A Phase I Trial of Iopofosine I 131 and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.Cancers · 2026Article
- Parallel Phase II Clinical Trials of Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma.JTO clinical and research reports · 2025Article
- Refractory Multiple Myeloma in a West Highland White Terrier: Clinical Presentations and Therapeutic Interventions.Animals : an open access journal from MDPI · 2025Article
- Autophagy modulates glioblastoma cell sensitivity to Selinexor-mediated XPO1 inhibition.Neuro-oncology · 2025Article
- Review
- Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment.Iranian journal of medical sciences · 2025Review
- Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.Clinical hematology international · 2025Review
- Adverse events reporting of XPO1 inhibitor - selinexor: a real-word analysis from FAERS database.Scientific reports · 2024Article
- Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study).Life (Basel, Switzerland) · 2024Article
- Beyond oncology: Selinexor's journey into anti-inflammatory treatment and long-term management.Frontiers in immunology · 2024Review
- Treatment of multiple myeloma with selinexor: a review.Therapeutic advances in hematology · 2024Review
- Current use of CAR T cells to treat multiple myeloma.Hematology. American Society of Hematology. Education Program · 2023Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 1 institution in 1 country.
Dan T VoglDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
David DingliDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Robert Frank CornellDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Carol Ann HuffDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Sundar JagannathDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Divaya BhutaniDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Jeffrey ZonderDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Rachid BazDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Ajay NookaDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Joshua RichterDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Craig ColeDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Ravi VijDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Andrzej JakubowiakDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Rafat AbonourDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Gary SchillerDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Terri L ParkerDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Luciano J CostaDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
David KaminetzkyDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
James E HoffmanDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Andrew J YeeDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Ajai ChariDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
David SiegelDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Rafael FonsecaDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Scott Van WierDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Gregory AhmannDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Ilsel LopezDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Michael KauffmanDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Sharon ShachamDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Jean-Richard Saint-MartinDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Carla D PicklesimerDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Cassandra Choe-JuliakDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
A Keith StewartDan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.
Johns Hopkins University · US
Funding
Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4MProject 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5MNCI NIH HHS P30 CA022453NCI NIH HHS P50 CA186781
Abstract
Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through nuclear retention of tumor suppressor proteins and the glucocorticoid receptor, along with inhibition of translation of oncoprotein mRNAs. We studied selinexor in combination with low-dose dexamethasone in patients with multiple myeloma refractory to the most active available agents. Patients and Methods This phase II trial evaluated selinexor 80 mg and dexamethasone 20 mg, both orally and twice weekly, in patients with myeloma refractory to bortezomib, carfilzomib, lenalidomide, and pomalidomide (quad-refractory disease), with a subset also refractory to an anti-CD38 antibody (penta-refractory disease). The primary end point was overall response rate (ORR). Results Of 79 patients, 48 had quad-refractory and 31 had penta-refractory myeloma. Patients had received a median of seven prior regimens. The ORR was 21% and was similar for patients with quad-refractory (21%) and penta-refractory (20%) disease. Among patients with high-risk cytogenetics, including t(4;14), t(14;16), and del(17p), the ORR was 35% (six of 17 patients). The median duration of response was 5 months, and 65% of responding patients were alive at 12 months. The most common grade ≥ 3 adverse events were thrombocytopenia (59%), anemia (28%), neutropenia (23%), hyponatremia (22%), leukopenia (15%), and fatigue (15%). Dose interruptions for adverse events occurred in 41 patients (52%), dose reductions occurred in 29 patients (37%), and treatment discontinuation occurred in 14 patients (18%). Conclusion The combination of selinexor and dexamethasone has an ORR of 21% in patients with heavily pretreated, refractory myeloma with limited therapeutic options.
Indexed as
Active Transport, Cell NucleusAdministration, OralAdultAgedAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneDose-Response Relationship, DrugExportin 1 ProteinFemaleHumansHydrazinesKaryopherinsMaleMiddle AgedMultiple MyelomaProgression-Free SurvivalDexamethasoneExportin 1 ProteinHydrazinesKaryopherinsReceptors, Cytoplasmic and NuclearselinexorTriazoles
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.